RecruitingPhase 4NCT06969755

Biomarkers to Enhance Early Schizophrenia Treatment

Sponsor

Northwell Health

Enrollment

180 participants

Start Date

Sep 30, 2025

Study Type

INTERVENTIONAL

Conditions

Schizophenia Disorder

Summary

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

Eligibility

Min Age: 18 YearsMax Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called aripiprazole, a drug called clozapine, and others for people with schizophenia disorder. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years to 35 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.